4.6

CiteScore

2.2

Impact Factor
  • ISSN 1674-8301
  • CN 32-1810/R
Subhasree Nag, Jiangjiang Qin, Kalkunte S. Srivenugopal, Minghai Wang, Ruiwen Zhang. The MDM2-p53 pathway revisited[J]. The Journal of Biomedical Research, 2013, 27(4): 254-271. DOI: 10.7555/JBR.27.20130030
Citation: Subhasree Nag, Jiangjiang Qin, Kalkunte S. Srivenugopal, Minghai Wang, Ruiwen Zhang. The MDM2-p53 pathway revisited[J]. The Journal of Biomedical Research, 2013, 27(4): 254-271. DOI: 10.7555/JBR.27.20130030

The MDM2-p53 pathway revisited

Funds: 

This work was supported by the National Institutes of Health (NIH) grants R01 CA112029 and R01 CA121211 and a Susan G Komen Foundation grant BCTR0707731 (to R.Z.).

More Information
  • Received Date: March 14, 2013
  • The p53 tumor suppressor is a key transcription factor regulating cellular pathways such as DNA repair, cell cycle, apoptosis, angiogenesis, and senescence. It acts as an important defense mechanism against cancer onset and progression, and is negatively regulated by interaction with the oncoprotein MDM2. In human cancers, the TP53 gene is frequently mutated or deleted, or the wild-type p53 function is inhibited by high levels of MDM2, leading to downregulation of tumor suppressive p53 pathways. Thus, the inhibition of MDM2-p53 interaction presents an appealing therapeutic strategy for the treatment of cancer. However, recent studies have revealed the MDM2-p53 interaction to be more complex involving multiple levels of regulation by numerous cellular proteins and epigenetic mechanisms, making it imperative to reexamine this intricate interplay from a holistic viewpoint. This review aims to highlight the multifaceted network of molecules regulating the MDM2-p53 axis to better un-derstand the pathway and exploit it for anticancer therapy.
  • Related Articles

    [1]Tiwari-Heckler Shilpa, Jiang Z. Gordon, Popov Yury, J. Mukamal Kenneth. Daily high-dose aspirin does not lower APRI in the Aspirin-Myocardial Infarction Study[J]. The Journal of Biomedical Research, 2020, 34(2): 139-142. DOI: 10.7555/JBR.33.20190041
    [2]Huan Liu, Shijiang Zhang, Yongfeng Shao, Xiaohu Lu, Weidong Gu, Buqing Ni, Qun Gu, Junjie Du. Biomechanical characterization of a novel ring connector for sutureless aortic anastomosis[J]. The Journal of Biomedical Research, 2018, 32(6): 454-460. DOI: 10.7555/JBR.31.20170011
    [3]Minbo Zang, Qiao Zhou, Yunfei Zhu, Mingxi Liu, Zuomin Zhou. Effects of chemotherapeutic agent bendamustine for nonhodgkin lymphoma on spermatogenesis in mice[J]. The Journal of Biomedical Research, 2018, 32(6): 442-453. DOI: 10.7555/JBR.31.20170023
    [4]Kaibo Lin, Shikun Zhang, Jieli Chen, Ding Yang, Mengyi Zhu, Eugene Yujun Xu. Generation and functional characterization of a conditional Pumilio2 null allele[J]. The Journal of Biomedical Research, 2018, 32(6): 434-441. DOI: 10.7555/JBR.32.20170117
    [5]Huanqiang Wang, Congying Yang, Siyuan Wang, Tian Wang, Jingling Han, Kai Wei, Fucun Liu, Jida Xu, Xianzhen Peng, Jianming Wang. Cell-free plasma hypermethylated CASZ1, CDH13 and ING2 are promising biomarkers of esophageal cancer[J]. The Journal of Biomedical Research, 2018, 32(6): 424-433. DOI: 10.7555/JBR.32.20170065
    [6]Eika S. Webb, Peng Liu, Renato Baleeiro, Nicholas R. Lemoine, Ming Yuan, Yaohe Wang. Immune checkpoint inhibitors in cancer therapy[J]. The Journal of Biomedical Research, 2018, 32(5): 317-326. DOI: 10.7555/JBR.31.20160168
    [7]Jiang-Jiang Qin, Sushanta Sarkar, Sukesh Voruganti, Rajesh Agarwal, Wei Wang, Ruiwen Zhang. Identification of lineariifolianoid A as a novel dual NFAT1 and MDM2 inhibitor for human cancer therapy[J]. The Journal of Biomedical Research, 2016, 30(4): 322-333. DOI: 10.7555/JBR.30.20160018
    [8]Sahitya K Denduluri, Zhongliang Wang, Zhengjian Yan, Jing Wang, Qiang Wei, Maryam K Mohammed, Rex C Haydon, Hue H Luu, Tong-Chuan He. Molecular pathogenesis and therapeutic strategies of human osteosarcoma[J]. The Journal of Biomedical Research, 2016, 30(1): 5-18. DOI: 10.7555/JBR.30.20150075
    [9]Lifeng Zhang, Ning Shao, Qianqian Yu, Lixin Hua, Yuanyuan Mi, Ninghan Feng. Association between p53 Pro72Arg polymorphism and prostate cancer risk: a meta-analysis[J]. The Journal of Biomedical Research, 2011, 25(1): 25-32. DOI: 10.1016/S1674-8301(11)60003-1
    [10]Zhenyu He, Chuanbing Shi, Hao Wen, Fanglong Li, Baolin Wang, Jie Wang. The potential of carcinoembryonic antigen, p53, Ki-67 and glutathion Stransferase-π as clinico-histopathological markers for colorectal cancer[J]. The Journal of Biomedical Research, 2010, 24(1): 51-57.

Catalog

    Article Metrics

    Article views (8857) PDF downloads (2419) Cited by()
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return